IDEA Collider: Innovation & Asymmetric Learning in Pharma

IDEA Pharma, SAI MedPartners
  • 5.0 (2)
  • LIFE SCIENCES
  • UPDATED SEMIMONTHLY

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s broken in traditional innovation models—and how do we fix it? 🎧 Listen and subscribe on all major platforms.

  1. Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping

    MAY 13

    Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping

    In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.  While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach.  Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development. The conversation also highlights Anocca’s first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms.  This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine.  Episode Timestamps  00:00 – Introduction to TCR-T and solid tumor challenges  00:48 – Meet Reagan Jarvis and Anocca  02:05 – From New Zealand to Sweden: founder journey  03:08 – Frustration that sparked the platform  04:33 – Why CAR-T struggles in solid tumors  07:24 – The advantage of vertical integration in biotech  09:23 – First non-viral clinical trial challenges  10:56 – Umbrella trials in pancreatic cancer (KRAS focus)  14:13 – Biomarkers and building a target library  17:08 – Software, data, and machine learning in TCR discovery  18:08 – Regulatory pathways for individualized therapies  19:19 – Commercial landscape and target bottlenecks  22:29 – Expanding beyond oncology and partnerships  23:51 – Building a biotech company in Sweden  27:12 – Misconceptions about T-cell biology  30:04 – Milestones and 5-year vision  32:32 – Advice for scientific founders  34:17 – Closing thoughts  Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Reagan Jarvis;  LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/  Website: https://www.anocca.com/     Follow IDEA Pharma  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    35 min
  2. Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds

    APR 27

    Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds

    In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations.  After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation.  The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment.  They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology.  Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth.  This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode  Timestamps  00:00 – Introduction and Vir’s transformation story  00:40 – Marianne De Backer’s 30+ year pharma journey  02:42 – Vir’s origins and post-COVID strategic pivot  04:42 – Taking over as CEO during a crisis  06:33 – Lessons from the biotech downturn (“biotech winter”)  08:56 – Astellas partnership and T-cell engager strategy  09:52 – ProXtend platform: masked T-cell engagers explained  13:24 – Clinical data, safety, and tumor targeting  15:32 – Integrating new teams and scientific expertise  17:38 – Expanding the pipeline (HER2, EGFR, oncology)  19:50 – Hepatitis delta program and commercialization plans  22:11 – Funding strategy and biotech market outlook  25:37 – FDA interactions and regulatory perspective  28:13 – AI in drug discovery and clinical trials (Daisy platform)  31:34 – Culture: grit, ingenuity, collaboration, authenticity  34:21 – Personal reflections and leadership mindset  35:46 – Closing thoughts  Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Marianne De Backer;  LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/  Website: https://www.vir.bio/      Follow IDEA Pharma On;  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    36 min
  3. Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi

    MAR 11

    Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi

    In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation.    Episode Timestamps;  00:00 Welcome to Idea Collider  00:18 Kymera 2026 Catalysts  02:33 De Risking with Degraders  02:54 Targeted Protein Degradation 101  06:20 KT-621 STAT6 Degrader 08:16 Rethinking Type 2 Disease Treatment 12:21 Nello’s Path to CEO  16:32 Building a Standalone Biotech  23:19 Partnering with Big Pharma  26:51 Culture and Office Energy  32:03 Capital Plan and Potential Launches 36:24 Belief and Execution Mindset  39:00 Life Outside the Lab  40:07 Where to Follow Kymera  40:35 Closing Thanks    Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Nello Mainolfi & Kymera LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/ Website: https://www.kymeratx.com/      Follow IDEA Pharma On;  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma/      Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

    41 min
  4. AI & Competitive Intelligence in Pharma: Smarter Decision-Making with SAI MedPartners

    FEB 26

    AI & Competitive Intelligence in Pharma: Smarter Decision-Making with SAI MedPartners

    In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making.  Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston, and Lucia Fernandez Barreiros, this conversation examines how cross-functional teams can interpret insights, manage uncertainty, and improve portfolio outcomes in complex drug development environments. The discussion covers artificial intelligence, asymmetric learning, forecasting challenges, strategic alignment, and the leadership mindset required to navigate innovation in biopharma.  SAI MedPartners is a global consultancy that provides strategic insights, competitive intelligence, market research, and commercialization strategy to pharmaceutical, biotechnology, and medical device companies across the product lifecycle. This episode is a must-listen for leaders working across drug development, commercialization strategy, and pharmaceutical innovation.  Keep up with the guests;  Erik Nordhoy - President at SAI MedPartners LLC https://www.linkedin.com/in/erik-nordhoy-6996241/  John Barry  - Executive Vice President at SAI MedPartners LLC https://www.linkedin.com/in/johnnbarry/  Matt Boucher, PhD - Director, Oncology BU, SAI MedPartners LLC https://www.linkedin.com/in/matthewbchr/  Jennifer Preston - VP, Artificial Intelligence Leader, SAI MedPartners LLC https://www.linkedin.com/in/jennifer-j-preston/  Lucia Fernandez Barreiros - Consulting Analyst, SAI MedPartners LLC https://www.linkedin.com/in/lucia-fernandez-barreiros-ba5260224/    Follow Mike Rea On;  Website: https://ideacollider.simplecast.com/  X: https://x.com/ideapharma  LinkedIn: https://www.linkedin.com/in/bigidea/      Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    53 min
  5. Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

    FEB 18

    Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

    In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases.   Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, affecting millions worldwide. Rather than the traditional “one drug, one disease” model, Alltrna is pursuing a mutation-targeted strategy that could treat multiple diseases with a single therapeutic platform.   Episode Timestamps; 00:00 Welcome to Idea Collider: Asymmetric Learning in Pharma 00:19 Meet Michelle Werner: Leading Alltrna’s tRNA Platform 02:09 From Cancer Clinic to Pharma: A Patient-First Career Path 06:18 Big Pharma vs Biotech CEO: Finding Your Authentic Leadership Style 09:37 Vulnerability & Psychological Safety: Building High-Trust Teams 11:46 A Personal Turning Point: Her Son’s Duchenne Diagnosis 17:11 Rare Disease Renegades: A Nonprofit to Accelerate Innovation 18:19 Why Flagship Pioneering: The Ecosystem Behind Alltrna 22:31 tRNA 101: Targeting Stop-Codon Disease Across Thousands of Conditions 28:46 Rethinking Trials, Indications & FDA Pathways for Mutation-First Medicines 33:49 From Preclinical to First-in-Human: Alltrna’s 2026 Milestones 36:49 What Keeps a CEO Up at Night + Final Takeaway: Is This Rare Disease’s Inflection Point?   Michelle also reflects on how her personal experience as a parent of a child with a rare condition fuels her commitment to accelerating therapies for patients who currently have few or no options.   This episode highlights a pivotal question for the industry: Are rare diseases at the same inflection point oncology experienced two decades ago?   Don't forget to Like, Share, Subscribe, Rate, and Review!   Keep up with Michelle Werner; LinkedIn: https://www.linkedin.com/in/michelle-c-werner/ Website: https://www.alltrna.com/   Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    41 min
  6. Revitalizing Pharma Collaborations: The Reblozyl Case Study

    12/22/2025

    Revitalizing Pharma Collaborations: The Reblozyl Case Study

    In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features insightful contributions from Robin, Jane, and Tracy, key players from Acceleron and Celgene, who share their experiences and the collaborative efforts that enabled them to redefine the market. The discussion covers the strategic approach to overcoming competitive benchmarking, the importance of a unified messaging strategy, and the critical role of internal and external collaboration. They also reflect on the impact of their efforts on the lives of many patients and offer advice for future teams working on complex drug development projects. The episode concludes with a recognition of the rare and valuable collaborative human elements that drove the success of the Reblozyl project. Episode Timestamps; 00:00 Introduction and Welcome 00:27 Rick's Background and Project Overview 02:31 Client Team Introductions 05:32 Collaboration and Challenges 13:29 Defining the Mechanism and Market Positioning 23:52 Communication and Alignment 27:48 Navigating Internal and External Communication 33:15 Launch, Reflections, and Lessons Learned 41:14 Final Thoughts and Acknowledgements   Keep up with the guests; Robyn Blackburn  - Director Global Commercial Strategy CAR-T at Kite Pharmahttps://www.linkedin.com/in/robyn-blackburn-805b8b13/Jayne Butler - Director of Strategic Initiatives at Fingerpaint Brandinghttps://www.linkedin.com/in/jaynebutler/Tracey Sacco - Former SVP Global Strategic Marketing at Acceleronhttps://www.linkedin.com/in/tracey-sacco-53 2a034/Rick Ritacco - Head of Growth and Innovationhttps://www.linkedin.com/in/rritacco/   Follow Mike Rea On; Website: https://ideacollider.simplecast.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    44 min
  7. Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan

    12/08/2025

    Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan

    In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease. Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech founder, and now leader inside a global pharmaceutical company. The conversation explores how human genetics, CRISPR base editing, lipid nanoparticle delivery, and asymmetric learning converged to create a potential lifelong solution to cardiovascular disease. They also dive deep into the ethics of gene editing, global access and pricing, early intervention versus chronic care, FDA regulatory challenges, and what the Verve–Lilly acquisition means for the future of cardiometabolic medicine. This episode is a must-listen for anyone interested in biotech innovation, gene therapy, cardiovascular disease, and the future of preventive medicine.   00:00 Introduction and Guest Welcome 01:16 Sekar Kathiresan's Early Life and Education 03:19 Founding Verve and Transition to Entrepreneurship 05:35 The Science Behind Verve's Mission 10:27 Challenges and Breakthroughs in Gene Editing 20:05 Regulatory Hurdles and First Human Trials 25:11 Ethical Considerations in Gene Editing 27:06 Introduction to Drug Delivery and Ethical Considerations 27:51 Historical Context and Pioneers in Medical Procedures 28:35 Commercial and Ethical Challenges in Medicine 29:32 Innovations in Cardiovascular Treatments 32:49 The Role of Gene Editing in Long-term Health 37:55 Strategic Partnerships and Industry Insights 45:08 Reflections on the US Medical Ecosystem 48:54 Conclusion and Future Outlook   Keep up with Sekar Kathiresan; LinkedIn: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/ Website: https://www.lilly.com/   Follow Mike Rea On; Website: https://ideacollider.simplecast.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    51 min
  8. Biotech Innovations and AI in Drug Development with Alex Telford:

    09/23/2025

    Biotech Innovations and AI in Drug Development with Alex Telford:

    In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows. The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation!   00:00 Welcome to Idea Collider 00:04 Introducing Alex Telford 01:59 Alex's Journey from UCL to Convoke Bio 05:29 The Mission and Work of Convoke Bio 07:57 Challenges in Pharma Decision Making 14:05 The Role of AI in Pharma 18:26 Knowledge Management and AI 27:58 Staying Updated in the Fast-Moving AI Field 30:25 AI's Impact on Industry Economics 31:38 AI in Clinical Trials and Drug Development 35:56 China's Role in Drug Discovery 39:24 Neuroscience and AI: Blurring the Lines 46:05 Future Predictions in Pharma 51:20 Addressing Cognitive Bias in Pharma 53:13 Concluding Thoughts and Future Directions   Keep up with Alex Telford; LinkedIn: https://www.linkedin.com/in/alexander-telford/ Website: atelfo.github.io X: https://twitter.com/atelfo Substack: atelfo.substack.com   Follow Mike Rea On; Website: https://www.ideapharma.com/ X: https://x.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

    54 min
See All (67)

Trailer

Ratings & Reviews

5
out of 5
2 Ratings

About

IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s broken in traditional innovation models—and how do we fix it? 🎧 Listen and subscribe on all major platforms.

Information

You Might Also Like